Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 3/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10808021 | 1.00 | CYP2C19 (0.54) | CYP2C19HIF1ATAAR1KCNN4MAPK1 | |
| SCHEMBL18660794 | 0.87 | CYP2C19 (0.44) | CYP2C19HIF1ATAAR1KCNN4MAPK1 | |
| SCHEMBL8612395 | 0.85 | CYP2C19 (0.47) | CYP2C19HIF1ATAAR1KCNN4MAPK1 | |
| SCHEMBL7040834 | 0.85 | CYP2C19 (0.52) | CYP2C19HIF1ATAAR1KCNN4MAPK1 | |
| SCHEMBL17710390 | 0.85 | CYP2C19 (0.47) | CYP2C19HIF1ATAAR1KCNN4MAPK1 | |
| SCHEMBL7040831 | 0.85 | CYP2C19 (0.52) | CYP2C19HIF1ATAAR1KCNN4MAPK1 | |
| SCHEMBL11817408 | 0.85 | CYP2C19 (0.47) | CYP2C19HIF1ATAAR1KCNN4MAPK1 | |
| SCHEMBL597345 | 0.85 | CYP2C19 (0.47) | CYP2C19HIF1ATAAR1KCNN4MAPK1 | |
| SCHEMBL27540234 | 0.85 | CYP2C19 (0.47) | CYP2C19HIF1ATAAR1KCNN4MAPK1 | |
| SCHEMBL28425133 | 0.84 | CYP2C19 (0.45) | CYP2C19HIF1ATAAR1KCNN4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6013848-A | REACTING SAID HEAVY POLYALKYLATED AROMATIC COMPOUND MIXTURE WITH BENZENE TO PRODUCE ETHYL BENZENE AND A POLYALKYLATED AROMATIC COMPOUND MIXTURE CONTAINING TETRAETHYL BENZENE AND LIGHTER POLYALKYLATED AROMATIC COMPOUND; TRANSALKYLATION | CATALYTIC DISTILLATION TECHNOLOGIES | 2000-01-11 | — | — | US | claimed |
| WO-2021043653-A1 | POLYMER COMPOSITION AND ARTICLE MADE FROM THE SAME | COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) | 2021-03-11 | — | — | WO | disclosed |
| EP-2641738-B1 | Planographic printing plate precursor and method for producing a planographic printing plate | FUJIFILM CORP (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-20130052564-A1 | POLYMER ELECTROLYTE MEMBRANE, MEMBRANE-ELECTRODE ASSEMBLY, AND SOLID POLYMER FUEL CELL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8114997-B2 | N4-acylcytosine nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-RE42015-E1 | N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7615316-B2 | Nonaqueous electrolytic solution and lithium secondary batteries | UBE INDUSTRIES, LTD. (JP) | 2009-11-10 | — | — | US | disclosed |
| US-20090176730-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20080275079-A1 | 3-Endo)-3-[2,2-Bis-(3-hydroxy-phenyl)-ethenyl]-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane bromide; chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, allergic rhinitis | GLAXO GROUP LIMITED | 2008-11-06 | — | — | US | disclosed |
| US-3983066-A | Solid, rapid setting, rigid polyurethanes | THE DOW CHEMICAL COMPANY (US) | 1976-09-28 | — | — | US | disclosed |
| US-3983063-A | Solid, rapid-setting, rigid polyurethanes | THE DOW CHEMICAL COMPANY (US) | 1976-09-28 | — | — | US | disclosed |
| US-3983064-A | Solid, rapid-setting, rigid polyurethanes | THE DOW CHEMICAL COMPANY (US) | 1976-09-28 | — | — | US | disclosed |
| US-3983065-A | Solid, rapid-setting, rigid polyurethanes | THE DOW CHEMICAL COMPANY (US) | 1976-09-28 | — | — | US | disclosed |
| US-3983069-A | Solid, rapid-setting, rigid polyurethanes | THE DOW CHEMICAL COMPANY (US) | 1976-09-28 | — | — | US | disclosed |
| US-3983068-A | Solid, rapid-setting, rigid polyurethanes | THE DOW CHEMICAL COMPANY (US) | 1976-09-28 | — | — | US | disclosed |
| US-3966662-A | Solid, rapid-setting, rigid polyurethanes | THE DOW CHEMICAL COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
| US-3966664-A | Solid, rapid-setting, rigid polyurethanes | THE DOW CHEMICAL COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
| US-3965073-A | Preparation of rapid setting non-elastomeric polyurethane compositions in the presence of ester-modified polyoxyalkylene compounds | THE DOW CHEMICAL COMPANY (US) | 1976-06-22 | — | — | US | disclosed |
| US-3956221-A | Rapid setting non-elastomeric polyurethane compositions containing a non-hydroxyl containing ester-modified polyoxylkylene compound | THE DOW CHEMICAL COMPANY (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176730-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, NT5C3B, PNP | CYP2C19 1411/4885HIF1A 4424/4885TAAR1 3972/4885 |
| US-20080275079-A1 | 3-Endo)-3-[2,2-Bis-(3-hydroxy-phenyl)-ethenyl]-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane bromide; chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, allergic rhinitis | CHRM3, EDNRB, BDKRB2 | CYP2C19 1979/4885HIF1A 2217/4885TAAR1 520/4885 |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, DUT, NT5C3B | CYP2C19 1391/4885HIF1A 4406/4885TAAR1 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.